Avalo Entered into an Exclusive WW License Agreement with Apollo to Develop and Commercialize AVTX-007 (camoteskimab) for Non-Eosinophilic Asthma
Shots:
- Avalo to receive $15M incl. $5M up front within 5 days of execution of the agreement & ~$10M for transfer activities & is also eligible to receive ~$74M in milestones along with royalties
- Apollo gets the rights to research, develop, manufacture & commercialize AVTX-007, currently in P-II (PEAK) trial for non-eosinophilic asthma & will also lead the future development of AVTX-007 incl. ongoing clinical trials along with continued clinical development in its selected therapeutic indications
- The collaboration will expand Apollo's pipeline with the addition of AVTX-007 in immunology & also helps to expand additional preclinical programs. Apollo plans to seek an opportunity to acquire clinical assets in areas of biological & therapeutic
Ref: GlobeNewswire | Image: Avalo therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
